Safety of apraclonidine eye drops in diagnosis of Horner syndrome in an outpatient pediatric ophthalmology clinic

Systemic Toxicity With Use of Apraclonidine Ophthalmic Drops in Pediatric Patients

“…These studies are small with limited ability to detect infrequent safety outcomes and contain insufficient information to define age-related or dose-related thresholds for safe use. One study in patients aged 1 month to 15 years noted no systemic AEs when apraclonidine was used in the setting of nasolacrimal occlusion, but there was no evidence to indicate whether this technique was a key modifiable factor for safety …”

“…One study in patients aged 1 month to 15 years noted no systemic AEs when apraclonidine was used in the setting of nasolacrimal occlusion, but there was no evidence to indicate whether this technique was a key modifiable factor for safety. 15…”

Systemic Toxicity With Use of Apraclonidine Ophthalmic Drops in Pediatric Patients

“…These studies are small with limited ability to detect infrequent safety outcomes and contain insufficient information to define age-related or dose-related thresholds for safe use. One study in patients aged 1 month to 15 years noted no systemic AEs when apraclonidine was used in the setting of nasolacrimal occlusion, but there was no evidence to indicate whether this technique was a key modifiable factor for safety …”

“…One study in patients aged 1 month to 15 years noted no systemic AEs when apraclonidine was used in the setting of nasolacrimal occlusion, but there was no evidence to indicate whether this technique was a key modifiable factor for safety. 15…”

A Rare Presentation of Guillain-Barré Syndrome With Associated Horner Syndrome: A Case Report

“…In Horner syndrome, the affected pupil and the tarsal muscle experience denervation hypersensitivity. Apraclonidine, an alpha-2 adrenergic agonist with weak alpha-1 adrenergic agonist activity, when applied topically, induces dilation of the affected pupil and potentially elevates the lid, while leaving the normal pupil unchanged [ 11 ]. Horner syndrome predominantly arises as an acquired condition, often stemming from systemic or local diseases or iatrogenic causes.…”

Update on pediatric cataract surgery

“… 120 , 135 , 136 Apraclonidine does not cross the blood-brain barrier as readily and may be safe in children older than 6 months. 137 , 138 If medications fail to control IOP and/or prevent progression of disease, surgical options include angle surgery, cyclophotocoagulation and tube shunt insertion.…”

Systemic Toxicity With Use of Apraclonidine Ophthalmic Drops in Pediatric Patients

“…These studies are small with limited ability to detect infrequent safety outcomes and contain insufficient information to define age-related or dose-related thresholds for safe use. One study in patients aged 1 month to 15 years noted no systemic AEs when apraclonidine was used in the setting of nasolacrimal occlusion, but there was no evidence to indicate whether this technique was a key modifiable factor for safety …”

“…One study in patients aged 1 month to 15 years noted no systemic AEs when apraclonidine was used in the setting of nasolacrimal occlusion, but there was no evidence to indicate whether this technique was a key modifiable factor for safety. 15…”

A Rare Presentation of Guillain-Barré Syndrome With Associated Horner Syndrome: A Case Report

“…In Horner syndrome, the affected pupil and the tarsal muscle experience denervation hypersensitivity. Apraclonidine, an alpha-2 adrenergic agonist with weak alpha-1 adrenergic agonist activity, when applied topically, induces dilation of the affected pupil and potentially elevates the lid, while leaving the normal pupil unchanged [ 11 ]. Horner syndrome predominantly arises as an acquired condition, often stemming from systemic or local diseases or iatrogenic causes.…”

Update on pediatric cataract surgery

“… 120 , 135 , 136 Apraclonidine does not cross the blood-brain barrier as readily and may be safe in children older than 6 months. 137 , 138 If medications fail to control IOP and/or prevent progression of disease, surgical options include angle surgery, cyclophotocoagulation and tube shunt insertion.…”

Systemic Toxicity With Use of Apraclonidine Ophthalmic Drops in Pediatric Patients

“…These studies are small with limited ability to detect infrequent safety outcomes and contain insufficient information to define age-related or dose-related thresholds for safe use. One study in patients aged 1 month to 15 years noted no systemic AEs when apraclonidine was used in the setting of nasolacrimal occlusion, but there was no evidence to indicate whether this technique was a key modifiable factor for safety …”

“…One study in patients aged 1 month to 15 years noted no systemic AEs when apraclonidine was used in the setting of nasolacrimal occlusion, but there was no evidence to indicate whether this technique was a key modifiable factor for safety. 15…”

A Rare Presentation of Guillain-Barré Syndrome With Associated Horner Syndrome: A Case Report

“…In Horner syndrome, the affected pupil and the tarsal muscle experience denervation hypersensitivity. Apraclonidine, an alpha-2 adrenergic agonist with weak alpha-1 adrenergic agonist activity, when applied topically, induces dilation of the affected pupil and potentially elevates the lid, while leaving the normal pupil unchanged [ 11 ]. Horner syndrome predominantly arises as an acquired condition, often stemming from systemic or local diseases or iatrogenic causes.…”

Update on pediatric cataract surgery

“… 120 , 135 , 136 Apraclonidine does not cross the blood-brain barrier as readily and may be safe in children older than 6 months. 137 , 138 If medications fail to control IOP and/or prevent progression of disease, surgical options include angle surgery, cyclophotocoagulation and tube shunt insertion.…”